Presently, however, Drp1 inhibitors are mostly discussed in the context of cancer and nervous system disorders, with little clinical research on PAH (Reddy, 2014; Han et al., 2021; Dhapola et al., 2022). This evidence concerns the gene DNM1L and pulmonary arterial hypertension.